The Social Cost of FDA’s Bias Against New TechnologyMobi Health News October 8, 2015
Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, authored an article in Mobi Health News titled “The Social Cost of FDA’s Bias Against New Technology.”
Following is an excerpt:
This mobile health technology is in fact quite important, and its development needs to be encouraged, not frustrated. If you already agree, please humor me while I make the case that the potential benefits from a societal standpoint outweigh the regulatory policy behind putting every new medical device through a substantial gauntlet.
Of course, each software developer presumably can make a case that their product will truly help patients. But at a higher level, I will focus specifically on the new, cutting-edge mobile health technologies that replace professionals.
Some healthcare professionals will want to shoot me for this, but I believe certain software that “replaces” the healthcare professional has significant, potential societal benefits.
There are good reasons we should want to have software that automates some of what physicians and other health professionals do.